N

Northern California Retina Vitreous Associates Medical Group | Mountain View, CA

Research site

(Unclaimed)

Location

2495 Hospital Drive Suite 545, Mountain View, California, United States of America

Site insights

Top conditions

Top treatments

Abicipar Pegol

AR-14034

ANX007

THR-149

SF0166

Sunitinib Malate

EYP-1901

Aflibercept

GB-102

CLS-AX

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 17 total trials

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.

Enrolling

Wet Age Related Macular Degeneration

wAMD

Drug: Aflibercept (2.0 mg)

Drug: EYP-1901

A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of ANX007 in Participants With Geographic Atrophy (GA) (ARCHER II)

The primary purpose of the study is to determine if IVT injections of ANX007 every month reduce vision loss in participants with GA secondary to age-...

Enrolling

Geographic Atrophy

Drug: ANX007

Other: Sham Administration

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME) (ALTITUDE®)

ABBV-RGX-314 is being developed as a novel, potential one-time gene therapy treatment for the treatment of Diabetic Retinopathy (DR) with and without...

Enrolling

Diabetic Retinopathy (DR)

Center-Involved Diabetic Macular Edema (CI-DME)

Genetic: ABBV-RGX-314 Dose 4

Biological: Aflibercept

Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD) (NOVA-1)

The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in...

Enrolling

Neovascular Age-related Macular Degeneration (nAMD)

Drug: AR-14034 SR implant lower dose

Drug: AR-14034 SR implant higher dose